Amgen Inc. vs Tata Motors Limited: Strategic Comparison

This in-depth comparison examines Amgen Inc. and Tata Motors Limited across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating Tata Motors Limited, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and Tata Motors Limited is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against ~$9.7B for Tata Motors Limited, while their respective market capitalizations stand at $228.2B and $17.5B. Amgen Inc. is headquartered in United States and Tata Motors Limited in India, and those different home markets shape how each company competes.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

Tata Motors Limited: Tata Motors' history is broader than its current legal perimeter. The brand story includes trucks, buses, passenger cars, the Nano, EVs and JLR, but the current listed Tata Motors Limited is the commercial-vehicles successor.

Amgen Inc. and Tata Motors Limited pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and Tata Motors Limited.

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

Tata Motors Limited business model: Tata Motors -- following an October 2025 demerger that split the historic company in two -- now refers specifically to the commercial-vehicle business: trucks, buses, and other heavy vehicles sold mostly to the Indian domestic market, plus a proposed international expansion through the pending Iveco Group acquisition. The passenger-vehicle business, Tata's EV operations, and Jaguar Land Rover (JLR) -- the UK luxury-SUV maker Tata acquired from Ford for $2.3 billion in 2008 -- now sit in a separately listed entity, Tata Motors Passenger Vehicles Limited, led by CEO Shailesh Chandra. The current, post-demerger Tata Motors Limited reported FY2026 consolidated revenue of about INR83,855 crore (roughly $8.7 billion), not comparable to the pre-demerger consolidated figures that included JLR's much larger revenue base. Tata has grown its commercial-vehicle scale through acquisition, including Daewoo Commercial Vehicle (2004) for South Korean heavy-truck technology, and has a proposed acquisition of European truck maker Iveco Group pending regulatory approval as of the FY2026 results. The commercial-vehicle demerger reflects a broader trend among diversified Indian conglomerates toward focused, pure-play listed entities that institutional investors can value more precisely than a combined structure spanning trucks, passenger cars, and an UK luxury brand with very different growth and margin profiles. Tata Motors Limited's post-demerger scale, while smaller than the pre-split combined entity, gives it a cleaner comparison set against other pure-play commercial-vehicle makers globally, including the Iveco Group it now aims to acquire.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of Tata Motors Limited.

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

Tata Motors Limited competitive advantage: Tata Motors' advantage is its scale in Indian commercial vehicles, deep dealer and service reach, Tata brand trust, engineering base and ability to bundle vehicles, spares, fleet tools and service.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and Tata Motors Limited each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

Tata Motors Limited growth strategy: Tata Motors is growing through next-generation trucks, buses, electric and alternative-fuel commercial vehicles, Fleet Edge, service parts, exports, operational discipline and the planned Iveco expansion.

A closer look at the financial trajectory of Amgen Inc. and Tata Motors Limited rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

Tata Motors Limited: The post-demerger Tata Motors Limited reported FY2026 (year to March 31, 2026) revenue from operations of ~$9.73B (INR83,855 Cr), up 44% from ~$6.75B (INR58,217 Cr), as wholesales rose 14% to about 428,000 units. The jump partly reflects the changed perimeter after the demerger, so it is not a clean like-for-like growth rate. Profit for the year fell 5.2% to ~$351M (INR3,030 Cr), weighed by one-time demerger costs (about $111M (INR960 Cr) in Q3) and new labour-code charges. Momentum carried into Q1 FY2027: revenue rose about 20% to ~$2.39B (INR20,576 Cr) and attributable profit rose 83% to ~$297M (INR2,560 Cr), helped by a one-time gain linked to Tata Capital, while commodity costs squeezed margins.